CHICAGO--(BUSINESS WIRE)--CytoCore Inc. (OTCBB:CYOE), the developer of a suite of cost-effective cervical cell collection devices for the early detection of cancerous and precancerous conditions, announced today that Chief Executive Officer Robert McCullough, Jr. has purchased 189,000 shares of the Company’s stock over the past weeks, at an average price of $0.26. Additionally, Summitcrest Capital LP, of which Mr. McCullough is the President, purchased 463,900 shares of the Company’s common stock in a range of $0.17 to $0.31.
